DOCSLIB.ORG

Fetal Anticonvulsant Syndrome

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Fetal Anticonvulsant Syndrome Fetal Anticonvulsant Syndrome A parent’s guide into FACS (Our kids don’t come with manuals!) Table of Contents ABOUT FOETAL ANTI-CONVULSANT SYNDROME NEW ZEALAND (FACS NZ)............................................ 4 ANTI-SEIZURE MEDICATIONS IN NEW ZEALAND ..................................................................................... 5 THE EXCLUSIVE CLUB ............................................................................................................................. 6 FETAL ANTICONVULSANT SYNDROME (FACS) ........................................................................................ 7 FETAL VALPROATE SYNDROME/FETAL VALPROATE SPECTRUM DISORDER ............................................. 8 FETAL CARBAMAZEPINE SYNDROME ..................................................................................................... 9 FETAL HYDANTOIN SYNDROME ........................................................................................................... 10 FETAL PRIMIDONE SYNDROME ............................................................................................................ 10 HOW TO GET A DIAGNOSIS.................................................................................................................. 11 FAMILY LIFE AND THE DIAGNOSIS ........................................................................................................ 12 SOME HELPFUL IDEAS.......................................................................................................................... 14 ACC ..................................................................................................................................................... 16 ADDITIONAL SUPPORT ORGANISATIONS OR HELPFUL LINKS ................................................................ 17 NB: There are many different terminologies being used such as anti-seizure, antiepileptic, or anticonvulsant medications. Whatever terminology you or your healthcare professional uses, we just want you to have the information. © 2020 FACS New Zealand 2 Disclaimer: Not all people of childbearing age, who take an anti-seizure medication during pregnancy will have children that are affected by Fetal Anticonvulsant Syndrome (FACS). Consultation with a specialist prior to getting pregnant is recommended. People who are pregnant or are planning to get pregnant should never stop taking their medication without speaking to a medical professional. I am me…you may not understand me, but believe in me, support me, and allow me to reach my full potential…I AM ME! © 2020 FACS New Zealand 3 About Foetal Anti-Convulsant Syndrome New Zealand (FACS NZ) Starting as a passionate group of people beginning a journey of positive change, it became evident early on that a charitable organisation dedicated solely to Fetal Anticonvulsant Syndromes was a necessity. This led to the official launch of FACS NZ in February 2015. FACS NZ Vision The understanding and recognition of what the different Foetal Anti- Convulsant syndromes are and how they can be prevented FACS NZ Mission To provide support, education and awareness of Foetal Anti- Convulsant Syndromes Leading this forward-thinking organisation is our Executive Officer, Denise Astill. Denise has hands on practical experience and knowledge that is not found in a book. She has lived experience of having loved ones who have been affected by Fetal Valproate Syndrome (FVS), as her twin daughters were diagnosed at 4 ½ years of age. Denise has become used to having to pave a way for recognition, knowledge, acceptance, education and support for FVS. Her girls were the very first cases accepted under Treatment Injury with ACC. This was a monumental achievement as it has led to future cases being accepted. At FACS NZ we provide information on our website, Facebook page, support and education, whether it be on an individualised basis, or to a larger group or community, awareness of the syndrome, and seek to decrease the likelihood of these syndromes. We also have Youth Ambassadors with lived experience of Fetal Valproate Syndrome. Please feel free to contact us: FACS NZ Email: [email protected] Website: www.facsnz.com Phone: 021 189 4483 Facebook: FACS New Zealand The future is exciting when we at FACS NZ think about the positive change that is beginning to occur, and know that we are leading this change. © 2020 FACS New Zealand 4 Anti-seizure medications in New Zealand Anti-seizure medications were primarily designed for use in seizure treatment, but they have also been used for mental health conditions, migraines, and pain management. Some people may know them as mood stabilisers. Anti-seizure medications being used in New Zealand are: • carbamazepine - Tegretol® • clobazam - Frisium® • clonazepam - Paxam®, Rivotril® • diazepam – DBL®, Stesolid® • ethosuximide - Zarontin® • gabapentin - Neurontin®, Arrow-Gabapentin®, Apo-Gabapentin® • lacosamide - Vimpat® • lamotrigine - Logem®, Mogine®, Lamictal®, Arrow-Lamotrigine®, Motrig® • levetiracetam - Keppra®, Everet®, Levetiracetam AFT® • lorazepam - Ativan® • oxcarbazepine - Trileptal® • phenobarbital – Phenobarbitone PSM® • phenytoin – Dilantin Infatabs® • pregabalin - Lyrica®, Pregabalin Pfizer® • primidone – Apo-Primidone® • retigabine – Trobalt® • rufinamide – Inovelon® • sodium valproate - Epilim® • topiramate - Topamax®, Topiramate Actavis® • vigabatrin – Sabril® (Please note that this list is not exhaustive and that brand names may change from time to time, so check with your healthcare professional) © 2020 FACS New Zealand 5 The Exclusive Club Welcome to the exclusive club of being a parent(s) or caregiver(s) of a child (or children) who has been diagnosed, or are in the process of being diagnosed, with Fetal Anticonvulsant Syndrome (FACS), Fetal Valproate Syndrome/Spectrum Disorder (sodium valproate or Epilim®), Fetal Carbamazepine Syndrome (carbamazepine or Tegretol®) Fetal Hydantoin Syndrome (phenytoin or Dilantin®), or Fetal Primidone (primidone or Apo-Primidone®). You are not alone, there are others here in New Zealand going through similar experiences, so welcome. This could be a time for you of acceptance, confirmation, or recognition of thoughts that you had been internalising or outwardly expressing for some time. For the vast majority it will also be a time for grieving. Grieving is a normal process, where there is no time limit, and one that varies from person to person. Allow yourself the time to grieve. To the childbearing person out there reading this and saying, “This is all my fault! I have done this to my child!” the next statement is very important for you to read, say it out loud and process. THIS IS NOT YOUR FAULT. You did not do this to your child. The medication is what has done this to your child, not you. THIS IS NOT YOUR FAULT! For this statement to truly sink in will probably take some time, and in all honesty for some people it remains with them. For the father’s out there you could possibly be in denial about the whole situation and thinking there is nothing wrong, or maybe you are going into the “fix it” mode, where you are going to fix everything. Unfortunately, there is no “fix” to the diagnosis, there is however acceptance, and strategies of how to set your family up for more successes. Reassure the childbearing person that it was not their fault. They did not do this to your child. It was the medication, not them. They will need to hear this often initially, as they will be blaming themselves. Life for everyone has changed significantly. Priorities, expectations, values, well just about everything will have changed. Life will undoubtedly bring struggles, difficulties, hardships and challenges, but it will also bring you enrichment, enlightenment and you will be touched in a way that will never be replaced. Your child will show you courage, love, and a strength that you would think is not humanly possible. Let this journey of the Exclusive Club turn into one of the Inclusive Club, where there is acceptance, awareness, education, support, and collaboration of understanding between everyone involved with your whanau. © 2020 FACS New Zealand 6 Fetal Anticonvulsant Syndrome (FACS) FACS (or the relevant syndrome) occurs when the anti-seizure medication that was taken by the childbearing person during pregnancy crosses the placenta and into the developing foetus. The diagnosis of FACS/respective individual syndrome, depending on what anti-seizure medication was taken) can only be made by a specialist, when the childbearing person, took the specific anti-seizure medication(s) during pregnancy and has a child with a combination of physical malformations, dysmorphic (facial) features, neurodevelopment or cognitive difficulties, and no other cause can be found for these difficulties e.g., genetic syndromes. With Fetal Valproate Spectrum Disorder (FVSD) the facial features do not need to be present to have been affected by the medication. When a diagnosis of FACS is made many variables are considered, such as the dosage of the anti-seizure medication (higher dosages carry increased risks), the anti-seizure medication itself (higher risks are associated with sodium valproate), and whether the anti-seizure medication was monotherapy (only a single type of anti-seizure being used) or polytherapy (more than one type of anti-seizure being used). When there is a child(ren) in the family with a confirmed diagnosis of FACS, and the childbearing person was on the same treatment regime as the confirmed child(ren), there is an increased risk
Load more

Recommended publications
  • United States July 2016 2 Table of Contents
    Deuterium Labelled Compounds United States July 2016 2 Table of Contents International Distributors 3 Corporate Overview 4 General Information 5 Pricing and Payment 5 Quotations 5 Custom Synthesis 5 Shipping 5 Quality Control 6 Quotations 6 Custom Synthesis 6 Shipping 6 Quality Control 6 Chemical Abstract Service Numbers 6 Handling Hazardous Compounds 6 Our Products are Not Intended for Use in Humans 7 Limited Warranty 7 Packaging Information 7 Alphabetical Listings 8 Stock Clearance 236 Products by Category 242 n-Alkanes 243 α-Amino Acids, N-Acyl α-Amino Acids, N-t-BOC Protected α-Amino Acid 243 and N-FMOC Protected α-Amino Acids Buffers and Reagents for NMR Studies 245 Detergents 245 Environmental Standards 246 Fatty Acids and Fatty Acid Esters 249 Flavours and Fragrances 250 Gases 253 Medical Research Products 254 Nucleic Acid Bases and Nucleosides 255 Pesticides and Pesticide Metabolites 256 Pharmaceutical Standards 257 Polyaromatic Hydrocarbons (PAHs), Alkyl-PAHs, Amino-PAHs, 260 Hydroxy-PAHs and Nitro-PAHs Polychlorinated Biphenyls (PCBs) 260 Spin Labels 261 Steroids 261 3 International Distributors C Beijng Zhenxiang H EQ Laboratories GmbH Australia K Technology Company Graf-von-Seyssel-Str. 10 Rm. 15A01, Changyin Bld. 86199 Augsburg Austria H No. 88, YongDingLu Rd. Germany Beijing 100039 Tel.: (49) 821 71058246 Belgium J China Fax: (49) 821 71058247 Tel.: (86) 10-58896805 [email protected] China C Fax: (86) 10-58896158 www.eqlabs.de Czech Republic H [email protected] Germany, Austria, China Czech Republic, Greece, Denmark I Hungary,
    [Show full text]
  • Campro Catalog Stable Isotope
    Introduction & Welcome Dear Valued Customer, We are pleased to present to you our Stable Isotopes Catalog which contains more than three thousand (3000) high quality labeled compounds. You will find new additions that are beneficial for your research. Campro Scientific is proud to work together with Isotec, Inc. for the distribution and marketing of their stable isotopes. We have been working with Isotec for more than twenty years and know that their products meet the highest standard. Campro Scientific was founded in 1981 and we provide services to some of the most prestigious universities, research institutes and laboratories throughout Europe. We are a research-oriented company specialized in supporting the requirements of the scientific community. We are the exclusive distributor of some of the world’s leading producers of research chemicals, radioisotopes, stable isotopes and environmental standards. We understand the requirements of our customers, and work every day to fulfill them. In working with us you are guaranteed to receive: - Excellent customer service - High quality products - Dependable service - Efficient distribution The highly educated staff at Campro’s headquarters and sales office is ready to assist you with your questions and product requirements. Feel free to call us at any time. Sincerely, Dr. Ahmad Rajabi General Manager 180/280 = unlabeled 185/285 = 15N labeled 181/281 = double labeled (13C+15N, 13C+D, 15N+18O etc.) 186/286 = 12C labeled 182/282 = d labeled 187/287 = 17O labeled 183/283 = 13C labeleld 188/288 = 18O labeled 184/284 = 16O labeled, 14N labeled 189/289 = Noble Gases Table of Contents Ordering Information.................................................................................................. page 4 - 5 Packaging Information ..............................................................................................
    [Show full text]
  • Hypothalamic Principles Necessary for the Release of Ovulating Hormone from the Adenohypophysis
    EFFECT OF AMINOGLUTETHIMIDE ON REPRODUCTIVE PROCESSES IN FEMALE RATS W. J. EVERSOLE and D. J. THOMPSON Department of Life Sciences, Indiana State University, Terre Haute, Indiana 47809, U.S.A. (Received "òlst January 1974) Summary. Adult female rats injected subcutaneously with 100 mg aminoglutethimide phosphate (AGP)/kg/day for 4 weeks failed to become pregnant when placed in cohabitation with males during the last 2 weeks of the injection period. Lower doses depressed the fertility rate and reduced the litter size: the average litter size of three of eleven rats given 50 mg/kg/day was 4\m=.\7 young and of four of eleven rats given 25 mg was 7\m=.\0 young. Twenty-nine controls averaged 10\m=.\1/litter. Doses of 100 mg AGP/kg/day stopped vaginal cycling, prevented ovulation in adults, and delayed dissolution of the vaginal membrane in pubertal rats. Histological studies of the ovaries from rats with initial ages of 17 or 21 days which were injected with 25 to 100 mg AGP/kg/day for 2 weeks showed an increase in the number and size of vesicular follicles. Treatment of 27-day-old rats with 25 mg/kg/day for 2 weeks reduced the number of CL and three of four rats given 50 mg had ovaries lacking such bodies; all control ovaries in this group contained CL. These findings are taken as evidence that AGP inhibits ovulation but does not prevent follicular maturation. INTRODUCTION Many pharmacological compounds originally developed as anaesthetics, tranquillizers and anticonvulsants modify endocrine structures and functions (see Gaunt, Chart & Renzi, 1965).
    [Show full text]
  • Mechanisms of Action of Antiepileptic Drugs
    Review Mechanisms of action of antiepileptic drugs Epilepsy affects up to 1% of the general population and causes substantial disability. The management of seizures in patients with epilepsy relies heavily on antiepileptic drugs (AEDs). Phenobarbital, phenytoin, carbamazepine and valproic acid have been the primary medications used to treat epilepsy for several decades. Since 1993 several AEDs have been approved by the US FDA for use in epilepsy. The choice of the AED is based primarily on the seizure type, spectrum of clinical activity, side effect profile and patient characteristics such as age, comorbidities and concurrent medical treatments. Those AEDs with broad- spectrum activity are often found to exert an action at more than one molecular target. This article will review the proposed mechanisms of action of marketed AEDs in the US and discuss the future of AEDs in development. 1 KEYWORDS: AEDs anticonvulsant drugs antiepileptic drugs epilepsy Aaron M Cook mechanism of action seizures & Meriem K Bensalem-Owen† The therapeutic armamentarium for the treat- patients with refractory seizures. The aim of this 1UK HealthCare, 800 Rose St. H-109, ment of seizures has broadened significantly article is to discuss the past, present and future of Lexington, KY 40536-0293, USA †Author for correspondence: over the past decade [1]. Many of the newer AED pharmacology and mechanisms of action. College of Medicine, Department of anti epileptic drugs (AEDs) have clinical advan- Neurology, University of Kentucky, 800 Rose Street, Room L-455, tages over older, so-called ‘first-generation’ First-generation AEDs Lexington, KY 40536, USA AEDs in that they are more predictable in their Broadly, the mechanisms of action of AEDs can Tel.: +1 859 323 0229 Fax: +1 859 323 5943 dose–response profile and typically are associ- be categorized by their effects on the neuronal [email protected] ated with less drug–drug interactions.
    [Show full text]
  • Stems for Nonproprietary Drug Names
    USAN STEM LIST STEM DEFINITION EXAMPLES -abine (see -arabine, -citabine) -ac anti-inflammatory agents (acetic acid derivatives) bromfenac dexpemedolac -acetam (see -racetam) -adol or analgesics (mixed opiate receptor agonists/ tazadolene -adol- antagonists) spiradolene levonantradol -adox antibacterials (quinoline dioxide derivatives) carbadox -afenone antiarrhythmics (propafenone derivatives) alprafenone diprafenonex -afil PDE5 inhibitors tadalafil -aj- antiarrhythmics (ajmaline derivatives) lorajmine -aldrate antacid aluminum salts magaldrate -algron alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol combined alpha and beta blockers labetalol medroxalol -amidis antimyloidotics tafamidis -amivir (see -vir) -ampa ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) subgroup: -ampanel antagonists becampanel -ampator modulators forampator -anib angiogenesis inhibitors pegaptanib cediranib 1 subgroup: -siranib siRNA bevasiranib -andr- androgens nandrolone -anserin serotonin 5-HT2 receptor antagonists altanserin tropanserin adatanserin -antel anthelmintics (undefined group) carbantel subgroup: -quantel 2-deoxoparaherquamide A derivatives derquantel -antrone antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine antineoplastics (arabinofuranosyl derivatives) fazarabine fludarabine aril-, -aril, -aril- antiviral (arildone derivatives) pleconaril arildone fosarilate -arit antirheumatics (lobenzarit type) lobenzarit clobuzarit -arol anticoagulants (dicumarol type) dicumarol
    [Show full text]
  • Membrane Stabilizer Medications in the Treatment of Chronic Neuropathic Pain: a Comprehensive Review
    Current Pain and Headache Reports (2019) 23: 37 https://doi.org/10.1007/s11916-019-0774-0 OTHER PAIN (A KAYE AND N VADIVELU, SECTION EDITORS) Membrane Stabilizer Medications in the Treatment of Chronic Neuropathic Pain: a Comprehensive Review Omar Viswanath1,2,3 & Ivan Urits4 & Mark R. Jones4 & Jacqueline M. Peck5 & Justin Kochanski6 & Morgan Hasegawa6 & Best Anyama7 & Alan D. Kaye7 Published online: 1 May 2019 # Springer Science+Business Media, LLC, part of Springer Nature 2019 Abstract Purpose of Review Neuropathic pain is often debilitating, severely limiting the daily lives of patients who are affected. Typically, neuropathic pain is difficult to manage and, as a result, leads to progression into a chronic condition that is, in many instances, refractory to medical management. Recent Findings Gabapentinoids, belonging to the calcium channel blocking class of drugs, have shown good efficacy in the management of chronic pain and are thus commonly utilized as first-line therapy. Various sodium channel blocking drugs, belonging to the categories of anticonvulsants and local anesthetics, have demonstrated varying degrees of efficacy in the in the treatment of neurogenic pain. Summary Though there is limited medical literature as to efficacy of any one drug, individualized multimodal therapy can provide significant analgesia to patients with chronic neuropathic pain. Keywords Neuropathic pain . Chronic pain . Ion Channel blockers . Anticonvulsants . Membrane stabilizers Introduction Neuropathic pain, which is a result of nervous system injury or lives of patients who are affected. Frequently, it is difficult to dysfunction, is often debilitating, severely limiting the daily manage and as a result leads to the progression of a chronic condition that is, in many instances, refractory to medical This article is part of the Topical Collection on Other Pain management.
    [Show full text]
  • NACE Bromine Chemistry Review Paper
    25 YEARS OF BROMINE CHEMISTRY IN INDUSTRIAL WATER SYSTEMS: A REVIEW Christopher J. Nalepa Albemarle Corporation P.O. Box 14799 Baton Rouge, LA 70898 ABSTRACT Bromine chemistry is used to great advantage in nature for fouling control by a number of sessile marine organisms such as sponges, seaweeds, and bryozoans. Such organisms produce small quantities of brominated organic compounds that effectively help keep their surfaces clean of problem bacteria, fungi, and algae. For over two decades, bromine chemistry has been used to similar advantage in the treatment of industrial water systems. The past several years in particular has seen the development of several diverse bromine product forms – one-drum stabilized bromine liquids, all-bromine hydantoin solids, and pumpable gels. The purpose of this paper is to review the development of bromine chemistry in industrial water treatment, discuss characteristics of the new product forms, and speculate on future developments. Keywords: Oxidizing biocide, bleach, bromine, bromine chemistry, sodium hypobromite, activated sodium bromide, Bromochlorodimethylhydantoin, Bromochloromethyethylhydantoin, Dibromodi- methylhydantoin,, BCDMH, BCMEH, DBDMH, stabilized bromine chloride, stabilized hypobromite INTRODUCTION Sessile marine organisms generate metabolites to ward off predators and deter attachment of potential micro- and macrofoulants. Sponges, algae, and bryozoans for example, produce a rich variety of bromine-containing compounds that exhibit antifoulant properties (Fig. 1).1,2,3 Scientists are actively studying these organisms to understand how they maintain surfaces that are relatively clean and slime- free.4 Brominated furanones isolated from the red algae Delisea pulchra, for example, have been found to interfere with the chemical signals (acylated homoserine lactones) that bacteria use to communicate with one another to produce biofilms.5,6 This work may eventually lead to more effective control of microorganisms in a number of industries such as industrial water treatment, oil and gas production, health care, etc.
    [Show full text]
  • Vitamin D Receptor Promotes Healthy Microbial Metabolites
    www.nature.com/scientificreports OPEN Vitamin D receptor promotes healthy microbial metabolites and microbiome Ishita Chatterjee1, Rong Lu1, Yongguo Zhang1, Jilei Zhang1, Yang Dai 2, Yinglin Xia1 ✉ & Jun Sun 1 ✉ Microbiota derived metabolites act as chemical messengers that elicit a profound impact on host physiology. Vitamin D receptor (VDR) is a key genetic factor for shaping the host microbiome. However, it remains unclear how microbial metabolites are altered in the absence of VDR. We investigated metabolites from mice with tissue-specifc deletion of VDR in intestinal epithelial cells or myeloid cells. Conditional VDR deletion severely changed metabolites specifcally produced from carbohydrate, protein, lipid, and bile acid metabolism. Eighty-four out of 765 biochemicals were signifcantly altered due to the Vdr status, and 530 signifcant changes were due to the high-fat diet intervention. The impact of diet was more prominent due to loss of VDR as indicated by the diferences in metabolites generated from energy expenditure, tri-carboxylic acid cycle, tocopherol, polyamine metabolism, and bile acids. The efect of HFD was more pronounced in female mice after VDR deletion. Interestingly, the expression levels of farnesoid X receptor in liver and intestine were signifcantly increased after intestinal epithelial VDR deletion and were further increased by the high-fat diet. Our study highlights the gender diferences, tissue specifcity, and potential gut-liver-microbiome axis mediated by VDR that might trigger downstream metabolic disorders. Metabolites are the language between microbiome and host1. To understand how host factors modulate the microbiome and consequently alter molecular and physiological processes, we need to understand the metabo- lome — the collection of interacting metabolites from the microbiome and host.
    [Show full text]
  • The Use of Central Nervous System Active Drugs During Pregnancy
    Pharmaceuticals 2013, 6, 1221-1286; doi:10.3390/ph6101221 OPEN ACCESS pharmaceuticals ISSN 1424-8247 www.mdpi.com/journal/pharmaceuticals Review The Use of Central Nervous System Active Drugs During Pregnancy Bengt Källén 1,*, Natalia Borg 2 and Margareta Reis 3 1 Tornblad Institute, Lund University, Biskopsgatan 7, Lund SE-223 62, Sweden 2 Department of Statistics, Monitoring and Analyses, National Board of Health and Welfare, Stockholm SE-106 30, Sweden; E-Mail: [email protected] 3 Department of Medical and Health Sciences, Clinical Pharmacology, Linköping University, Linköping SE-581 85, Sweden; E-Mail: [email protected] * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +46-46-222-7536, Fax: +46-46-222-4226. Received: 1 July 2013; in revised form: 10 September 2013 / Accepted: 25 September 2013 / Published: 10 October 2013 Abstract: CNS-active drugs are used relatively often during pregnancy. Use during early pregnancy may increase the risk of a congenital malformation; use during the later part of pregnancy may be associated with preterm birth, intrauterine growth disturbances and neonatal morbidity. There is also a possibility that drug exposure can affect brain development with long-term neuropsychological harm as a result. This paper summarizes the literature on such drugs used during pregnancy: opioids, anticonvulsants, drugs used for Parkinson’s disease, neuroleptics, sedatives and hypnotics, antidepressants, psychostimulants, and some other CNS-active drugs. In addition to an overview of the literature, data from the Swedish Medical Birth Register (1996–2011) are presented. The exposure data are either based on midwife interviews towards the end of the first trimester or on linkage with a prescribed drug register.
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0201562 A1 Lintner Et Al
    US 2011 O2O1562A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0201562 A1 Lintner et al. (43) Pub. Date: Aug. 18, 2011 (54) FORMULATIONS AND METHOD FOR Publication Classification TREATING BALDNESS (51) Int. Cl. A638/06 (2006.01) (75) Inventors: Karl Lintner, Paris (FR); Claire A6IP 7/4 (2006.01) Maschamberlin, Chevreuse (FR) (52) U.S. Cl. ....................................................... S14/20.7 (57) ABSTRACT (73) Assignee: SEDERMA, Le Perray-en-Yvelines cedex (FR) The present invention includes 1) a novel formulation for the treatment of hair loss comprising oleanolic acid (a 5C-reduc tase inhibitor), apigenin (a vasodilator), and biotinyl-GHK (a (21) Appl. No.: 13/092,328 cell metabolism stimulant), 2) a novel additive for the treat ment of hair loss comprising oleanolic acid, apigenin, bioti (22) Filed: Apr. 22, 2011 nyl-GHK and a delivery agent, 3) a personal care, cosmetic, and/or dermopharmaceutical composition comprising olean olic acid, apigenin, biotinyl-GHK, and at least one additional Related U.S. Application Data ingredient, and 4) a method for treating hair loss comprising (63) Continuation of application No. 1 1/097.666, filed on the administration of oleanolic acid, apigenin, and biotinyl Apr. 1, 2005, now abandoned. GHK. US 2011/02O1562 A1 Aug. 18, 2011 FORMULATIONS AND METHOD FOR turn reduce levels of dihydrotestosterone and thereby slow, TREATING BALDNESS prevent, or even reverse hair loss, particularly in men. The present invention includes formulations and methods for CROSS-REFERENCE TO RELATED addressing this issue. The present invention comprises olean APPLICATIONS olic acid, apigenin, biotinyl-GHK as active ingredients.
    [Show full text]
  • 3315S.Full.Pdf
    [CANCER RESEARCH (SUPPL.) 42, 3315S-3321 S. August 1982] 0008-5472/82/0042-0000$02.00 Basic Studies on Aminoglutethimide1 Hilton A. Salhanick Department of Population Sciences, Harvard School of Public Health, and Department of Obstetrics and Gynecology. Harvard Medical School, Boston. Massachusetts 02115 Abstract gical attempts to remove the naturally occurring steroidal hor mones on the other. The latter approach includes the admin Aminoglutethimide (AG), a bicyclic substance with two opti istration of tamoxifen, a target-receptor competitor of estro cally active isomers, inhibits the cholesterol side-chain cleav gens. Current thought is that AG acts by inhibiting steroido- age (SCO and aromatase systems by blocking the terminal genesis at the aromatase sites. cytochrome P-450s. AG interacts with these cytochromes to The purpose of this contribution is to review the actions of induce typical type II, low-spin spectra; the amount of spectral AG and attempt to relate them to therapeutic rationale. change correlates directly with the amount of enzymatic inhi bition. AG acts by preventing reduction of the cytochrome, an obligate step preceding oxygénationof substrate. The apparent Chemical Considerations K, of D(+ )-AG is about 2.5 times less than the K, of L(-)-AG in AG has 2 rings and an ethyl appendage (Chart 1). It resem inhibiting SCC and about 40 times less in inhibiting aromatase. bles glutethimide (Doriden), which lacks the amine. Since glu- The spectral Ks ratios of the D- and L-enantiomers for P-450scc tethimide has little or no antisteroidogenic activity, it follows and P-450a,omataseare2.5 and 5, respectively, in the presence that the amine is necessary for this biological activity.
    [Show full text]